Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) announced its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.63), Bloomberg Earnings reports. Tetraphase Pharmaceuticals had a negative net margin of 2,005.74% and a negative return on equity of 112.91%. The business had revenue of $4.10 million during the quarter, compared to analysts’ expectations of $1.59 million. During the same period last year, the business earned ($0.58) earnings per share. The business’s revenue for the quarter was up 355.6% on a year-over-year basis.

In related news, insider Jacques Dumas sold 17,500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 22nd. The shares were sold at an average price of $6.00, for a total value of $105,000.00. Following the transaction, the insider now owns 17,500 shares in the company, valued at $105,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 5.50% of the company’s stock.

A number of brokerages have weighed in on TTPH. Zacks Investment Research cut shares of Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, October 5th. BMO Capital Markets lifted their price target on shares of Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the company an “outperform” rating in a research report on Wednesday, October 4th. ValuEngine cut shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Needham & Company LLC reiterated a “hold” rating on shares of Tetraphase Pharmaceuticals in a research report on Thursday, July 27th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $13.00 price target on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, September 12th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $12.96.

TRADEMARK VIOLATION NOTICE: “Tetraphase Pharmaceuticals Inc (TTPH) Posts Earnings Results” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/11/02/tetraphase-pharmaceuticals-inc-ttph-posts-earnings-results.html.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Earnings History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.